A genome-wide screen identified ARHGAP35 as a regulator of regorafenib resistance in liver cancer [0.03%]
基因组广泛筛查确定ARHGAP35作为肝癌regorafenib耐药性的调节因子
Kun Chen,Miaomiao Zhang,Yuexin Liu et al.
Kun Chen et al.
Regorafenib, a multikinase inhibitor, is widely used to treat hepatocellular carcinoma. However, chemoresistance poses a significant challenge to its long-term efficacy. This study conducted a genome-wide CRISPR/Cas9 knockout screen in live...
Multifaceted transcriptional reprogramming supports oxaliplatin chemoresistance in colorectal cancer cells [0.03%]
转录重编程支持结直肠癌细胞奥沙利铂耐药性多面相机制
Gizem Calibasi-Kocal,Hasan Kurter,Zerrin Isik
Gizem Calibasi-Kocal
Oxaliplatin resistance remains a critical barrier to effective colorectal cancer treatment. The molecular mechanisms underlying this resistance are not fully understood, highlighting the need to define the transcriptional alterations that c...
Adiponectin Receptor 1-vascular endothelial growth factor axis mediates resistance to epidermal growth factor receptor-targeted therapy in nasopharyngeal carcinoma [0.03%]
脂肪细胞脂联素受体1-血管内皮生长因子轴介导了鼻咽癌表皮生长因子受体靶向治疗的耐药性
Zilu Cheng,Xiaohong Peng,Shuting Wu et al.
Zilu Cheng et al.
Nasopharyngeal carcinoma (NPC) is highly prevalent in Southeast Asia and southern China, with most patients diagnosed at advanced stages. Although epidermal growth factor receptor (EGFR)-targeted therapies have shown clinical promise, their...
Low relative dose intensity adjuvant chemotherapy in elderly patients with breast cancer: predictors and impact on survival [0.03%]
老年乳腺癌患者辅助化疗的低相对剂量强度及其预后因素和对生存期的影响
Allan Ramos-Esquivel,David Romero-Orocu,Raquel Mora-Hidalgo
Allan Ramos-Esquivel
Chemotherapy improves outcomes in patients with high-risk early or locally advanced breast cancer, but older adults often experience higher toxicity that leads to treatment delays, dose reductions, and reduced relative dose intensity (RDI)....
Temsirolimus targets chemoresistant uveal melanoma via mammalian target of rapamycin inhibition and enhances chemotherapy [0.03%]
雷帕霉素哺乳动物靶点抑制剂通路靶向治疗化疗耐药性脉络膜黑色素瘤并增敏化疗药物疗效
Qing Huang,Xuan Jiang,Na Tao
Qing Huang
Chemotherapy resistance remains a major challenge in the treatment of uveal melanoma, necessitating the identification of novel therapeutic strategies. In this study, we established chemoresistant uveal melanoma cell lines by exposing paren...
Real-world treatment patterns and survival outcomes in patients with metastatic castration-resistant prostate cancer in France: lessons from the prospective OPALE study [0.03%]
法国转移性去势抵抗性前列腺癌患者的真实治疗模式和生存结果：来自前瞻性OPALE研究的启示
Josephine Papet,Laetitia Augusto-Pelegrin,François Christy et al.
Josephine Papet et al.
In metastatic castration-resistant prostate cancer (mCRPC), several treatments are available, including androgen-receptor pathway inhibitors (ARPis) and chemotherapy (CT). There is a lack of real-world prospective data on treatment sequence...
Observational Study
Anti-cancer drugs. 2025 Nov 1;36(10):805-811. DOI:10.1097/CAD.0000000000001756 2025
Circular RNA SMARCA5 inhibits cholangiocarcinoma via microRNA-95-3p/tumor necrosis factor receptor associated factor 3 axis: Erratum [0.03%]
环状RNA SMARCA5通过microRNA-95-3p/肿瘤坏死因子受体相关因子3轴抑制胆管癌：勘误
Guangxin Wang,Xia Gao,Zhijun Sun et al.
Guangxin Wang et al.
Pembrolizumab treatment in SMARCA4-deficient nonsmall cell lung cancer: high tumor mutational burden and programmed death-ligand 1(+) expression on circulating tumor cells for real-time monitoring: a case report [0.03%]
帕博利珠单抗治疗SMARCA4缺陷型非小细胞肺癌：高肿瘤突变负荷和循环肿瘤细胞中程序性死亡配体1阳性表达的实时监测：一例报告
Youjun Deng,Yan Huang,Songhua Cai et al.
Youjun Deng et al.
Nonsmall cell lung cancer (NSCLC) with SMARCA4 deficiency represents a rare subset of lung tumors characterized by early metastasis, poor response to chemotherapy, and unfavorable prognosis. Established therapy strategies for SMARCA4-defici...
Serum heat shock protein family A member 9 protein as a biomarker for bortezomib resistance and poor prognosis in patients with multiple myeloma [0.03%]
血浆热休克蛋白家族A成员9作为硼替佐米耐药和多发性骨髓瘤不良预后的生物标志物
Lin Chen,Shuang Gao,Li Lin et al.
Lin Chen et al.
Bortezomib resistance in multiple myeloma (MM) is a significant clinical challenge that limits the long-term effectiveness. Currently, there is a lack of reliable biomarkers to predict bortezomib resistance. Previous studies reported that s...